Ocumension Therapeutics will convene its 2026 annual general meeting (AGM) on 30 June 2026 at 10:00 a.m. on the 56th Floor, One Museum Place Office Building, No. 669 Xinzha Road, Shanghai.

Key agenda items:

1. 2025 Results • Shareholders will vote to adopt the audited consolidated financial statements and the reports of the board and auditor for the year ended 31 December 2025.

2. Board Composition and Remuneration • Ratification of all acts of Director Mr. Zhenyu Zhang since the 2025 AGM. • Re-elections: Dr. Lian Yong Chen and Mr. Yanling Cao as non-executive directors; Mr. Zhenyu Zhang as an independent non-executive director. • Election: Ms. Beibei Zhuang as an independent non-executive director. • The board will be authorised to fix directors’ remuneration.

3. Auditor Appointment • Re-appointment of Deloitte Touche Tohmatsu with board-determined remuneration.

4. Capital Mandates • General mandate allowing the board to issue, allot or deal with new shares and convertible securities up to 20% of issued share capital (excluding treasury shares). • Authority to repurchase up to 10% of issued shares (excluding treasury shares). • Extension of the issuance mandate by the number of shares bought back under the repurchase mandate.

5. Share Incentive Schemes • Refresh of the combined share option and share award scheme mandate limit to 8% of issued shares (excluding treasury shares). • Within that limit, a sub-limit of 0.8% is set for grants to service providers.

Administrative Dates:

• Register closure: 24 – 30 June 2026 (both days inclusive). • Share transfer deadline for AGM eligibility: 4:30 p.m., 23 June 2026. • Proxy form deadline: 10:00 a.m., 28 June 2026.

The notice confirms no immediate plans for new share issuance, and any share repurchases will be executed only when deemed beneficial to shareholders.